CLINICAL_TRIALS
ClinicalTrials.gov record update
Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04061980
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:56.866999+00:00
- Published At
- 2026-04-13T00:00:00+00:00
- Record Updated At
- 2026-04-13
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["BRAF NP_004324.2:p.V600M", "BRAF V600E Mutation Present", "Metastatic Thyroid Gland Carcinoma", "Refractory Thyroid Gland Carcinoma", "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"- protocolSection.identificationModule.nctId
"NCT04061980"- protocolSection.identificationModule.officialTitle
"Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.